Lupin releases generic Pred Forte

Lupin is introducing prednisolone acetate ophthalmic suspension, 1%, which is a generic of AbbVie’s Pred Forte Ophthalmic Suspension.

Since it is the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy exclusivity.

Prednisolone acetate ophthalmic suspension, 1%, is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Pred Forte had a market value of $198 million per IQVIA August 2024 data.

[Read more:Lupin rolls out generic Doxil]

“The launch of prednisolone acetate ophthalmic Suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions,” said Vinita Gupta, CEO of Lupin. “This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation.”